Biotechnology M&A » By The Online Investor Staff, updated Fri., Apr. 26, 1:16 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #76 of 83 |
Slide #76. PerkinElmer — Shanghai Haoyuan Biotech Co., Ltd.,
Acquirer:
PerkinElmer (PKI)
Acquiree:
Shanghai Haoyuan Biotech Co., Ltd.,
Details:
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, announced today that it has completed the acquisition of Shanghai Haoyuan Biotech Co., Ltd., a China-based infectious disease diagnostics company. The acquisition extends PerkinElmer's capabilities into nucleic acid blood screening and in the growing molecular clinical diagnostics market in China, further strengthening the Company's position as a diagnostics leader in China as well as across the globe.
PerkinElmer provides products, services and solutions for the diagnostics, life sciences and applied markets. Co. ‘s segments are: Discovery and Analytical Solutions and Diagnostics. Co.'s Discovery and Analytical Solutions segment serves: the life sciences, which consist of the life sciences research market and laboratory services market; and applied markets, which consist of environmental, food and industrial markets. Co.'s Diagnostics segment provides instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians and medical research personnel. Co.'s Diagnostics segment is focused on reproductive health, immunodiagnostics, diagnostics and applied genomics.
Open the PKI Page at The Online Investor »
|
|||||||||
Open the PKI Page at The Online Investor (in a new window) »
 Free PKI Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (2.83 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: PKI Stock Forecast Based on Zacks ABR data; powered by Xignite |
